[HTML][HTML] Recent advances in the development of sialyltransferase inhibitors to control cancer metastasis: A comprehensive review
Metastasis accounts for the majority of cancer-associated mortalities, representing a huge
health and economic burden. One of the mechanisms that enables metastasis is …
health and economic burden. One of the mechanisms that enables metastasis is …
Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules
A Hazrati, K Malekpour, H Khorramdelazad… - Biomarker …, 2024 - Springer
Mesenchymal stromal/stem cells (MSCs) are used in many studies due to their therapeutic
potential, including their differentiative ability and immunomodulatory properties. These cells …
potential, including their differentiative ability and immunomodulatory properties. These cells …
[HTML][HTML] Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
K Boelaars, L Goossens-Kruijssen… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers.
Despite the successful application of immune checkpoint blockade in a range of human …
Despite the successful application of immune checkpoint blockade in a range of human …
Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions
K Boelaars, E Rodriguez, ZR Huinen, C Liu… - Communications …, 2024 - nature.com
Despite recent advances in cancer immunotherapy, pancreatic ductal adenocarcinoma
(PDAC) remains unresponsive due to an immunosuppressive tumor microenvironment …
(PDAC) remains unresponsive due to an immunosuppressive tumor microenvironment …
Comprehensive landscape of m6A regulator-related gene patterns and tumor microenvironment infiltration characterization in gastric cancer
B Peng, Y Lin, G Yi, M Lin, Y Xiao, Y Qiu, W Yao… - Scientific Reports, 2024 - nature.com
The epigenetic regulation of N6-methyladenosine (m6A) has attracted considerable interest
in tumor research, but the potential roles of m6A regulator-related genes, remain largely …
in tumor research, but the potential roles of m6A regulator-related genes, remain largely …
[HTML][HTML] Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands
K Boelaars, Y van Kooyk - Trends in Cancer, 2024 - cell.com
Advances in immunotherapy have revolutionized cancer treatment, yet many patients do not
show clinical responses. While most immunotherapies target T cells, myeloid cells are the …
show clinical responses. While most immunotherapies target T cells, myeloid cells are the …
Blood leukocytes as a non-invasive diagnostic tool for thyroid nodules: a prospective cohort study
F Wang, D Zhao, W Xu, Y Liu, H Sun, S Lu, Y Ji, J Jiang… - BMC medicine, 2024 - Springer
Background Thyroid nodule (TN) patients in China are subject to overdiagnosis and
overtreatment. The implementation of existing technologies such as thyroid ultrasonography …
overtreatment. The implementation of existing technologies such as thyroid ultrasonography …
A generic noninvasive neuromotor interface for human-computer interaction
Ctrl-labs at Reality Labs, D Sussillo, P Kaifosh… - bioRxiv, 2024 - biorxiv.org
Since the advent of computing, humans have sought computer input technologies that are
expressive, intuitive, and universal. While diverse modalities have been developed …
expressive, intuitive, and universal. While diverse modalities have been developed …
Antibody-lectin chimeras for glyco-immune checkpoint blockade
Despite the curative potential of checkpoint blockade immunotherapy, a majority of patients
remain unresponsive to existing treatments. Glyco-immune checkpoints–interactions of cell …
remain unresponsive to existing treatments. Glyco-immune checkpoints–interactions of cell …
Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors
M Spiga, E Martini, MC Maffia, F Ciceri… - Seminars in …, 2024 - Springer
Adoptive cell therapy (ACT) using Chimeric Antigen Receptor (CAR) and T Cell Receptor
(TCR) engineered T cells represents an innovative therapeutic approach for the treatment of …
(TCR) engineered T cells represents an innovative therapeutic approach for the treatment of …